Only in Titles

Search results for: Monoclonal

paperclip

#32272489   2020/04/09 To Up

Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.

Bevacizumab treatment is subject to large interpatient variability in efficacy, which may partly be explained by differences in complex bevacizumab pharmacokinetic characteristics that influence bevacizumab exposure. Exposure-response relationships have been identified for other monoclonal antibodies. We aimed to identify possible exposure-survival relationships in bevacizumab-treated patients with metastatic colorectal cancer (mCRC).
Apostolos Papachristos, Polychronis Kemos, Haralabos Kalofonos, Gregory Sivolapenko

2270 related Products with: Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.



Related Pathways

paperclip

#32272396   2020/04/02 To Up

The possible of immunotherapy for COVID-19: A systematic review.

The novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstratedthat although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.
Akram AminJafari, Sorayya Ghasemi

2887 related Products with: The possible of immunotherapy for COVID-19: A systematic review.

1 G100μg 100 G1.0 mg1 kit100 TESTS250 mg0.1 mg

Related Pathways

paperclip

#32272158   2020/04/06 To Up

Clinical Utility of Serum IgG4 Measurement.

This article will review the structure and function of IgG4, methods of measuring serum IgG4 concentrations, clinical conditions associated with increased and decreased serum IgG4, and the test characteristics of serum IgG4 in the diagnosis and management of Immunoglobulin G4-Related Disease (IgG4-RD). The four subclasses of IgG were discovered in 1964 through experiments on monoclonal IgG in patients with myeloma. Since 2001, interest in measuring serum IgG subclasses has increased dramatically due to the emergence of IgG4-RD, a multisystem fibroinflammatory condition wherein polyclonal serum IgG4 concentration is increased in approximately 70% of cases. Increased serum IgG4 typically manifests as a restriction in the anodal gamma region on serum protein electrophoresis, often with beta-gamma bridging, and can be mistaken as a monoclonal protein or polyclonal increase in IgA. Limitations of current clinical methods used in quantitation of serum IgG4 concentrations will be discussed, including the common immunonephelometric assays and LC-MS/MS based assays. Polyclonal IgG4 elevation is not specific for IgG4-RD, and may also occur in conditions such as eosinophilic granulomatosis with polyangiitis (EGPA), lymphoma, and multicentric Castleman disease (MCD). Race and gender differences also affect interpretation of serum IgG4 concentrations, for instance Asians have a higher serum IgG4 concentration than Whites and males have a higher concentration than females.
Julia L Varghese, Angela W S Fung, Andre Mattman, Tien T T Quach, Deonne Thaddeus V Gauiran, Mollie N Carruthers, Luke Y C Chen

1727 related Products with: Clinical Utility of Serum IgG4 Measurement.

10 ml100mg1 kit(96 Wells)96T1ml

Related Pathways

paperclip

#32271944   2020/04/09 To Up

Vimentin citrullinationprobedby a novel monoclonal antibody serves as a specific indicator for reactive astrocytes in neurodegeneration.

Vimentin citrullination, the calcium (Ca )-dependentpeptidylarginine deiminase (PAD)-mediated conversion of anarginine residue of vimentin to a citrulline residue,has emerged as a pathophysiological outcome ofautoimmune diseases and neurodegeneration. However, the roles, functions, and expression of citrullinated vimentinhave not yet been elucidated because available antibodies are limited.
Byungki Jang, Mo-Jong Kim, Yun-Jung Lee, Akihito Ishigami, Yong-Sun Kim, Eun-Kyoung Choi

2522 related Products with: Vimentin citrullinationprobedby a novel monoclonal antibody serves as a specific indicator for reactive astrocytes in neurodegeneration.

1 ml25 µg25 µg100 TESTS0.25 mg0.2 mg0.2 mg100ul4 Membranes/Box1mg4 Membranes/Box100ug

Related Pathways

paperclip

#32271918   2020/04/09 To Up

A novel monoclonal antibody cross-reactive with both human and mouse α9 integrin useful for therapy against rheumatoid arthritis.

The present study introduces a novel monoclonal anti-α9 integrin antibody (MA9-413) with human variable regions, isolated by phage display technology. MA9-413 specifically binds to both human and mouse α9 integrin by recognizing a conserved loop region designated as L1 (amino acids 104-122 of human α9 integrin). MA9-413 inhibits human and mouse α9 integrin-dependent cell adhesion to ligands and suppresses synovial inflammation and osteoclast activation in a mouse model of arthritis. This is the first monoclonal anti-α9 integrin antibody that can react with and functionally inhibit both human and mouse α9 integrin. MA9-413 allows data acquisition both in animal and human pharmacological studies without resorting to surrogate antibodies. Since MA9-413 showed certain therapeutic effects in the mouse arthritis model, it can be considered as a useful therapy against rheumatoid arthritis and other α9 integrin-associated diseases.
Masaharu Torikai, Hirofumi Higuchi, Nobuchika Yamamoto, Daisuke Ishikawa, Hirotada Fujita, Katsunari Taguchi, Fumihiko Sakai, Kenji Soejima, Toshihiro Nakashima

2681 related Products with: A novel monoclonal antibody cross-reactive with both human and mouse α9 integrin useful for therapy against rheumatoid arthritis.

25 µg25 µg100 TESTS1mg100 ul1 mg0.1 mg1 mg0.1 mg100ul0.1 mg100ug

Related Pathways

paperclip

#32271823   2020/04/09 To Up

Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody.

Monoclonal antibody derivatives are promising drugs for the treatment of various diseases due to their high matrix metalloproteinases (MMP) active site specificity. We studied the effects of a novel antibody, SDS3, which specifically recognizes the mature active site of MMP9/2 during ventricular remodeling progression in a mouse model of chronic volume overload (VO).
Lena Cohen, Irit Sagi, Einat Bigelman, Inna Solomonov, Anna Aloshin, Jeremy Ben-Shoshan, Zach Rozenbaum, Gad Keren, Michal Entin-Meer

1327 related Products with: Cardiac remodeling secondary to chronic volume overload is attenuated by a novel MMP9/2 blocking antibody.

100ug Lyophilized0,25ml / 50 test250 ug100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug Lyophilized200 ug100ug Lyophilized

Related Pathways

paperclip

#32271687   // To Up

Development of Novel Mouse Monoclonal Antibodies Against Human CD19.

CD19 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is expressed in normal and neoplastic B cells, and it modulates the threshold of B cell activation for amplifying B cell receptor signaling. Blinatumomab (a CD3-CD19-bispecific T cell-engaging antibody) and tisagenlecleucel (genetically modified T cells that express a CD19 chimeric antigen receptor [CART-19]) provide significant benefits for patients with CD19-positive relapsed or refractory B cell malignancies. In this study, we first employed the Cell-Based Immunization and Screening (CBIS) method to produce anti-CD19 monoclonal antibodies using CD19-overexpressing cells for both immunization and screening. One established clone-CMab-1-proved to be useful in flow cytometry assays against lymphoma cell lines, such as BALL-1, P30/OHK, and Raji. Second, the extracellular domain of CD19 was immunized into mice, and enzyme-linked immunosorbent assays were performed for the first screening. One established clone-CMab-3-was determined to be useful for Western blotting and immunohistochemical analysis. Due to their complementary utility, a combination of CMab-1 (established using CBIS) and CMab-3 (established using conventional method) could be useful for the pathological analysis of CD19.
Shinji Yamada, Mika K Kaneko, Yusuke Sayama, Teizo Asano, Masato Sano, Miyuki Yanaka, Takuro Nakamura, Saki Okamoto, Saori Handa, Yu Komatsu, Yoshimi Nakamura, Yoshikazu Furusawa, Junko Takei, Yukinari Kato

2587 related Products with: Development of Novel Mouse Monoclonal Antibodies Against Human CD19.

200.00 ug100 ug1 mg1 mL50 TESTS1 mg1mg50 TESTS1 mg0.1mg100.00 ug1mg

Related Pathways

paperclip

#32271462   // To Up

Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?

The outbreak of Sars-CoV-2 (COVID-19) poses serious challenges to people's health worldwide. The management of the disease is mostly supportive, and respiratory failure from acute respiratory distress syndrome is the leading cause of death in a significant proportion of affected patients. Preliminary data point out that dramatic increase in IL-6 and subsequent cytokine release syndrome may account for the development of fatal interstitial pneumonia. Inhibition of IL-6 by blocking its specific receptor with monoclonal antibodies has been advocated as a promising attempt. Here we assess the potential utility of myo-Inositol, a polyol already in use for treating the newborn Respiratory Distress Syndrome, in downregulating the inflammatory response upon Sars-CoV-2 infection. Myo-Inositol proved to reduce IL-6 levels in a number of conditions and to mitigate the inflammatory cascade, while being devoid of any significant side effects. It is tempting to speculate that inositol could be beneficial in managing the most dreadful effects of Sars-CoV-2 infection.
M Bizzarri, A S Laganà, D Aragona, V Unfer

2139 related Products with: Inositol and pulmonary function. Could myo-inositol treatment downregulate inflammation and cytokine release syndrome in SARS-CoV-2?

16 Arrays/Slide16 Arrays/Slide16 Arrays/Slide100 MG96T 1 G16 Arrays/Slide16 Arrays/Slide100 MG1250 mg

Related Pathways

paperclip

#32271353   2020/04/09 To Up

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1), such as the humanized monoclonal antibody durvalumab, have shown durable clinical responses in several tumor types. However, concerns about the safety and feasibility of PD-1/PD-L1 blockade in HIV-1-infected individuals have led to the exclusion of these patients from clinical trials on cancer immunotherapies.
Maria Gonzalez-Cao, Teresa Morán, Judith Dalmau, Javier Garcia-Corbacho, Jillian W P Bracht, Reyes Bernabe, Oscar Juan, Javier de Castro, Remei Blanco, Ana Drozdowskyj, Jordi Argilaguet, Andreas Meyerhans, Julia Blanco, Julia G Prado, Jorge Carrillo, Bonaventura Clotet, Bartomeu Massuti, Mariano Provencio, Miguel A Molina-Vila, Clara Mayo de Las Casa, Monica Garzon, Peng Cao, Chung-Ying Huang, Javier Martinez-Picado, Rafael Rosell

2625 related Products with: Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.

100ug Lyophilized 5 G100ug Lyophilized 100ul5 500 MG

Related Pathways

paperclip

#32270937   // To Up

[Widal's triad : clinical manifestations, pathophysiology and therapeutic advances].

NSAID-Exacerbated respiratory disease (also known as Samter's or Widal's triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs. The pathogenesis of this chronic inflammation arises from an imbalance in arachidonic acid metabolism, leading to an increase in pro- inflammatory cysteinyl-leukotrienes. The treatment is based on drug management of asthma and polyps and, in advanced situations, surgical management of polyposis. Monoclonal antibodies have shown promising results in the further medical treatment of this entity.
Sophie Vandenberghe-Dürr, Basile Nicolas Landis, Peter Jandus

1009 related Products with: [Widal's triad : clinical manifestations, pathophysiology and therapeutic advances].



Related Pathways